A European partnership has introduced a novel method for producing pharmaceutical active ingredients (APIs) through continuous-flow chemistry, real-time monitoring, and AI-guided adjustments. The PIPAC initiative, led by De Dietrich, Alysophil, Bruker, and Novalix, presents a more adaptable option compared to conventional batch production, which typically involves prolonged scaling phases and heavy resource use.
Continuous vs. Batch: A Shift in Production
Conventional API manufacturing depends on batch systems, where ingredients undergo sequential mixing, reaction, and separation in large vessels. Transitioning these methods to larger scales often requires months of testing. In contrast, the PIPAC framework employs continuous synthesis, processing materials in a steady flow while AI and real-time analytics ensure precision. This approach was validated using fentanyl, a tightly controlled API, demonstrating its ability to manage detailed production demands. While the pilot focused on synthesis, later stages like filtration and drying remain outside its current scope.
Strengthening Supply Chains and Local Adaptability
The project supports industry moves to reduce overdependence on Asia’s dominant API production centers. By enabling smaller, adaptable manufacturing setups, the technology could spread production networks, minimizing exposure to geopolitical or health-related disruptions. The partners emphasize that their system also cuts scaling risks and improves efficiency by identifying quality issues sooner.
The collaboration involved specialized contributions: Novalix developed the continuous synthesis process, Bruker supplied real-time analytical tools, Alysophil designed the AI control system, and De Dietrich assembled the hardware and automation. The successful trial suggests potential for GMP-compatible adaptations, though additional testing is required.
Frédéric Guichard, De Dietrich’s executive director, described the project as a turning point for API production, addressing vulnerabilities in supply chains, national production control, and operational flexibility. The consortium plans to expand the technology’s application across pharmaceutical sectors.
Widespread adoption could reshape manufacturing toward decentralized, responsive operations, but regulatory approvals and industry acceptance pose significant obstacles. The demonstration proves feasibility, yet full-scale implementation hinges on demonstrating economic viability and compliance at larger scales.
The consortium’s next phase will concentrate on refining the system for broader pharmaceutical use, with an eye toward overcoming existing barriers. This initiative marks a potential leap forward in API production methods, though its long-term impact will be shaped by how effectively it addresses practical and regulatory demands.
